Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Advanced Solid Tumors Appropriate for Treatment With Either Nivolumab or Pembrolizumab: early-phase trial registry
1 of 1 indexed Advanced Solid Tumors Appropriate for Treatment With Either Nivolumab or Pembrolizumab trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #11,370 of 28,707 conditions by registered trial count.
1 US clinical trials · 1 currently recruiting · #11,370 of 28,707 conditions by registered trial count
Advanced Solid Tumors Appropriate for Treatment With Either Nivolumab or Pembrolizumab: 1 US clinical trial tracked, 1 recruiting.
Advanced Solid Tumors Appropriate for Treatment With Either Nivolumab or Pembrolizumab is the subject of 1 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most active sponsor is Vaxiion Therapeutics, running 1 of these trials.
Enrollment posture brief
Registry condition advanced-solid-tumors-appropriate-for-treatment-with-either-nivolumab-or-pembrol
OPEN 1 | RECR 100% | LATE 0 | EARLY 1 | RANK #11370 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Aortic Arch Aneurysm (100% recruiting · 5 trials)
Advanced Solid Tumors Appropriate for Treatment With Either Nivolumab or Pembrolizumab lists 1 open slots (100% of 1 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Advanced Solid Tumors Appropriate for Treatment With Either Nivolumab or Pembrolizumab on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Advanced Solid Tumors Appropriate for Treatment With Either Nivolumab or Pembrolizumab is recruiting above its size-band peers.
1 of 1 indexed trials (100%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Open and recent trials
1 total, page 1 of 1
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Advanced Solid Tumors Appropriate for Treatment With Either Nivolumab or Pembrolizumab records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Advanced Solid Tumors Appropriate for Treatment With Either Nivolumab or Pembrolizumab trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Advanced Solid Tumors Appropriate for Treatment With Either Nivolumab or Pembrolizumab page
1 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 1 Advanced Solid Tumors Appropriate for Treatment With Either Nivolumab or Pembrolizumab trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Vaxiion Therapeutics sponsors the most Advanced Solid Tumors Appropriate for Treatment With Either Nivolumab or Pembrolizumab trials on record, review their full trial history before evaluating a specific study. See Vaxiion Therapeutics's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Advanced Solid Tumors Appropriate for Treatment With Either Nivolumab or Pembrolizumab condition card totals 1 registered trials; most-linked intervention Nivolumab or pembrolizumab; top US site state Ohio. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.